Filing Flows › Syndax Pharmaceuticals (SNDX) › Q3 2025
Syndax Pharmaceuticals (SNDX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 3, 2025
Syndax Pharmaceuticals (SNDX) reported revenue of $45.9M for the third quarter 2025 (Q3 2025), +267% from a year earlier and +21% from the quarter before. Operating margin was -125.2%, net loss $60.7M (132.4% of revenue).
Syndax Pharmaceuticals, Q3 2025: revenue $45.9M (+267% year over year), operating margin -125.2%, net loss $60.7M, operating cash flow −$70.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.9M | +21% | +267% |
| Operating profit | −$57.4M | — | — |
| Net earnings | −$60.7M | — | — |
| Operating cash flow | −$70.5M | — | — |
What changed
Revenue was $45.9M in Q3 2025, up 267% year over year and up 21% from the previous quarter. Product was the largest line at 70% of revenue.
Operating costs exceeded revenue by $57.4M, an operating margin of -125.2%. Total costs grew 1% against revenue growth of 267%. The fastest-growing cost line was General & admin (+44%). The quarter ended with a net loss of $60.7M, narrower than the previous quarter's $71.8M loss.
Operating cash flow was −$70.5M. Non-cash charges added back $3.0M of depreciation and $12.1M of share-based compensation. Working capital and other items used $24.9M.
Questions
What was Syndax Pharmaceuticals' revenue in the third quarter 2025?
Syndax Pharmaceuticals (SNDX) reported revenue of $45.9M for the third quarter 2025 (Q3 2025), +267% from a year earlier and +21% from the quarter before.
Was Syndax Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $57.4M (-125.2% of revenue) and net loss $60.7M.